Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy

July 23, 2018

Clinical studies with Biocept's Target Selector™ to evaluate the use of circulating tumor cells in disease assessment, surveillance and monitoring

SAN DIEGO, July 23, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will work with Moores Cancer Center at UC San Diego Health to conduct two clinical studies in patients with a variety of solid tumors. These studies will use Biocept's Target Selector™ liquid biopsy assays to detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) and compare results with findings from CT or PET scans.

The first study is designed to determine the feasibility of using liquid biopsy to predict disease recurrence in patients with Stage II or III cancer at high risk for recurrence. The second study will evaluate the feasibility of using liquid biopsy to predict response to therapy in patients with metastatic solid tumors. The studies are designed to evaluate Biocept's CTC and ctDNA assays in multiple cancer types, but will focus primarily on CTC biomarkers in patients diagnosed with breast, lung, and colon cancer.

"Despite recent advances in chemotherapy and radiation, risk for post-resection disease recurrence in patients with stage II or stage III solid tumors remains unacceptably high," said Razelle Kurzrock, M.D., Center for Personalized Cancer Therapy and Clinical Trials Office director, Moores Cancer at UC San Diego Health. "The current standard of care to assess disease recurrence is CT imaging, which may only detect recurrence after significant organ damage has occurred. Detecting disease recurrence in these patients with a blood sample may enable more rapid and comprehensive treatment options."

"We are enthusiastic about working with UC San Diego Health on these clinical studies to further demonstrate the clinical utility of our Target Selector™ platform and our ability to obtain biomarker information from both CTCs and ctDNA using a simple blood sample," said Biocept's President and Chief Executive Officer Michael Nall. "In breast cancer for example, our unique CTC platform has advantages over the use of liquid biopsies that rely solely on next generation sequencing, including the ability to detect gene amplifications and protein biomarkers, which are critical in the diagnosis and treatment of patients with breast cancer. We believe that clinical results from our patented technologies can provide physicians with important information to better predict a patient's response to therapy and monitor their disease progress and recurrence, which can lead to better patient outcomes."

About Biocept

Biocept, Inc. is a molecular diagnostics company with commercialized assays for biomarker analysis for lung, breast, gastric, colorectal and prostate cancers, and melanoma. The Company uses its proprietary liquid biopsy technology to provide physicians with information to help treat and monitor patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to help inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the outcomes of patients diagnosed with cancer, the results of the clinical studies and ability to use circulating tumor cells in disease assessment, surveillance and monitoring, and our ability to enable more rapid and comprehensive treatment options for patients diagnosed with cancer, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.

View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-and-uc-san-diego-moores-cancer-center-announce-collaboration-to-study-feasibility-of-liquid-biopsy-to-predict-disease-recurrence-in-solid-tumors-and-response-to-therapy-300684663.html

SOURCE Biocept, Inc.

Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100, OR Media Contact: Trevelino/Keller, Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109